Tesamorelin: structure, nomenclature and handling

Tesamorelin is a 44-amino-acid peptide. Its sequence corresponds to human growth hormone-releasing hormone, usually abbreviated GHRH — a hypothalamic peptide that is itself 44 residues long. In sequence terms, tesamorelin is that peptide with one deliberate addition.

The addition is a trans-3-hexenoyl group attached to the N-terminus. This is a short unsaturated fatty acid chain, and its presence is the single structural feature separating tesamorelin from native GHRH. The modification is at the amino terminus specifically because that region is where the peptide is most vulnerable to enzymatic cleavage.

Dipeptidyl peptidase-4 cleaves native GHRH rapidly at the N-terminal end, which is what makes the unmodified peptide short-lived in biological media. Blocking that position with an acyl group is a standard strategy in peptide engineering: the sequence responsible for receptor engagement is left intact while the site of proteolytic attack is sterically obstructed.

Tesamorelin is characterized against the GHRH receptor, a class B G-protein-coupled receptor. Because the receptor-binding region of the sequence is unmodified, its engagement profile at that receptor is closely comparable to the native peptide's — the modification addresses stability rather than binding.

Tesamorelin appears in the literature under the development code TH9507, and occasionally as the acetate salt form, which is how peptides of this kind are typically isolated and supplied. The salt form affects the mass of material weighed out but not the identity of the peptide itself.

The generic name follows the -relin stem, which is used across peptides that act as releasing-hormone analogues. Recognising that stem places an unfamiliar name into the right functional family immediately: sermorelin, examorelin and tesamorelin all share it, and all are analogues of releasing hormones rather than of the hormones released.

GHRH itself appears under several names in older literature, including somatocrinin and somatoliberin, and its 29-residue N-terminal fragment is catalogued as GRF(1-29) or sermorelin. Those fragments are related to tesamorelin by sequence but are distinct molecular entities.

Characterization of a 44-residue peptide is more demanding than for a short sequence, simply because there is more of it to get wrong during synthesis. Mass spectrometry confirms the intact molecular mass, and for a peptide of this length the observed mass is also informative about whether the N-terminal acyl modification is present as intended — an unmodified chain differs from the modified one by a defined mass increment.

High-performance liquid chromatography resolves the main peak from related substances. In a long synthetic peptide the most common related substances are deletion sequences, where a single residue failed to couple during synthesis. These differ from the target by one amino acid and can be difficult to separate, which is part of why the chromatogram is worth inspecting rather than reading the headline purity figure alone.

Amino acid analysis is sometimes reported alongside these methods. It hydrolyses the peptide and quantifies the constituent amino acids, providing an orthogonal confirmation of composition that does not depend on the same instrumentation as the mass measurement.

HEEZ Research supplies tesamorelin in a single format: a 10 mg lyophilized vial. There is no second strength in the current catalogue, so the format decision that arises with two-size products does not apply here.

The material is supplied as a lyophilized powder. Freeze-drying removes water and leaves the peptide as a solid, which is markedly more stable than the same peptide in solution and tolerates ambient shipping temperatures without refrigeration in transit.

A 10 mg vial of a 44-residue peptide contains fewer molar units than 10 mg of a short peptide would, because molar quantity is mass divided by molecular weight and this molecule is comparatively heavy. That distinction matters when protocols are specified in molar rather than mass terms.

The relationship is the same as for any lyophilized peptide: concentration equals mass divided by volume. A 10 mg tesamorelin vial reconstituted with 1 ml of diluent gives 10 mg per ml; with 2 ml it gives 5 mg per ml; with 5 ml, 2 mg per ml.

Bacteriostatic water is the usual diluent where a vial will be entered more than once, its 0.9% benzyl alcohol content acting as the preservative that permits repeat entry. Where a single entry is planned, sterile water without preservative is also used.

peptcalc.com will perform this conversion directly — enter the 10 mg vial mass and the concentration a protocol calls for, and it returns the volume to add. For molar concentrations the peptide's molecular weight is needed as well, and that figure appears on the certificate of analysis.

As with any peptide, diluent is introduced gently down the vial wall rather than directly onto the lyophilized cake, and the vial is swirled rather than shaken. Long peptides are if anything more prone to aggregation under mechanical stress than short ones.

Sealed lyophilized tesamorelin is ambient-stable for the duration of transit, so no cold chain or insulated packaging is required for shipping. On receipt the vial goes to refrigeration and is kept out of direct light.

Reconstituted tesamorelin is held refrigerated and used within the window the receiving facility's protocols specify. Solutions of GHRH-family peptides are generally treated as short-lived compared with the lyophilized form, and repeated freeze-thaw cycling is avoided.

The N-terminal acyl modification improves resistance to enzymatic cleavage in biological media but confers no special advantage against the physical degradation routes that matter in storage — aggregation, oxidation and adsorption to container surfaces. Standard peptide handling still applies in full.

The certificate records what an independent facility measured for one specific batch of tesamorelin. Its value lies in being batch-specific: a certificate for a different lot describes different material, so the first check is that the lot number on the document matches the vial.

The identity section compares observed molecular mass against the theoretical mass for the modified 44-residue sequence. Because the trans-3-hexenoyl group contributes a defined mass, a result matching the unmodified peptide's mass rather than the modified one would indicate a materially different compound.

The purity figure is the HPLC main-peak area as a percentage of total peak area, and the attached chromatogram shows how that figure was arrived at. For a long peptide it is worth looking at whether the impurities are a few discrete peaks or a broad cluster, since the two suggest different synthesis problems.

Peptide content or net peptide content is sometimes reported separately from purity. It accounts for counter-ions and residual water, and it is the figure that determines how much actual peptide a nominal 10 mg represents.